REGENXBIO Inc. (RGNX) News
Follow REGENXBIO Inc. (RGNX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 30 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Full Transcript: Regenxbio Q2 2026 Earnings Call
Regenxbio (NASDAQ: RGNX ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire
LIVE | Oct 05, 2026, 10:59 AM UTC
L
Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
REGENXBIO Inc. NASDAQ:RGNX
NEWS | Sep 23, 2026, 09:09 PM UTC
L
REGENXBIO and UPenn Reach $39 Million Patent Settlement With Sarepta Over Elevidys
REGENXBIO and the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics and Catalent to resolve patent litigation tied to AAVrh74-based gene therapies, including Elevidys. Sarepta will
NEWS | Sep 23, 2026, 08:15 PM UTC
L
RGNX: Late-stage gene therapy programs show strong efficacy, with pivotal data and regulatory filings imminent
The company is advancing late-stage gene therapy programs in DMD and ophthalmology, with RGX-202 showing strong efficacy and safety data and a BLA submission planned for early next year. Large pivotal trials in wet AMD a
NEWS | Sep 15, 2026, 02:02 PM UTC
L
RGNX: Late-stage gene therapy programs show strong efficacy, with financial runway into Q4 2027
The company is advancing late-stage gene therapy programs in DMD and retina, with RGX-202 showing strong efficacy and safety, and pivotal wet AMD trials with AbbVie targeting significant reduction in injection burden. Fi
NEWS | Sep 15, 2026, 01:24 PM UTC
L
REGENXBIO to participate in upcoming investor conferences
REGENXBIO said it will participate in the Baird 2026 Global Healthcare Conference and a Fireside Chat on Tuesday, September 15 at 8:30 a.m. ET in New York, NY.
EQUITY | Sep 08, 2026, 11:05 AM UTC
L
RGNX - REGENXBIO to Participate in Upcoming Investor Conferences
RGNX - REGENXBIO to Participate in Upcoming Investor Conferences
EQUITY | Sep 08, 2026, 11:05 AM UTC
L
REGENXBIO (RGNX) faces shareholder claims investigation by Johnson Fistel
Johnson Fistel, PLLP says it investigates claims on behalf of long-term shareholders of REGENXBIO Inc. (RGNX), according to TradeXchange Newsdesk.
REGULATION | Aug 25, 2026, 05:00 PM UTC
L
Regenxbio (RGNX) appoints Greg Ciongoli to strengthen board
Regenxbio appoints Greg Ciongoli to its board of directors, according to TradeXchange Newsdesk.
EQUITY | Aug 25, 2026, 11:05 AM UTC
M
RGNX falls 23% premarket on FDA headlines
RGNX shares fall 23% in premarket trading after FDA headlines, with no further catalyst provided in the wire.
REGULATION | Aug 24, 2026, 12:01 PM UTC
L
RGNX - REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
RGNX - REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
EQUITY | Aug 24, 2026, 11:06 AM UTC
L
Regenxbio and NS Pharma evaluate additional RGX-121 data
Regenxbio and NS Pharma are evaluating additional data for RGX-121, according to the market alert, with no catalyst or magnitude supplied.
EQUITY | Aug 24, 2026, 11:05 AM UTC
H
Regenxbio says FDA places clinical hold on RGX-121
Regenxbio says the FDA places a clinical hold on RGX-121 after spine MRI findings and does not expect to resubmit the RGX-121 BLA in the near term.
REGULATION | Aug 24, 2026, 11:05 AM UTC
L
RGNX RGNX - REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
RGNX RGNX - REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
EARNINGS | Aug 06, 2026, 11:05 AM UTC
L
RGNX RGNX - REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - Clic
RGNX RGNX - REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
EARNINGS | Aug 03, 2026, 11:05 AM UTC
L
Deals priced today • CLBK (Columbia Financial) 167M share IPO, priced at $10.00, by KBW, Piper & Brean • RGNX 10M share Spot Secondary, pric
Deals priced today • CLBK (Columbia Financial) 167M share IPO, priced at $10.00, by KBW, Piper & Brean • RGNX 10M share Spot Secondary, priced at $9.00, by MSCO, JPMC, Leerink & Mizuho Deal to be priced • RPT Secondary a
EQUITY | Jul 17, 2026, 12:26 PM UTC
H
Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling around 2% on Friday. Shares of Intuitive Surgical Inc (NASDAQ: ISRG ) fell sharply in pre-market trading after the company reported second-q
EARNINGS | Jul 17, 2026, 12:02 PM UTC
L
RGNX -17% premarket after offering headlines
RGNX -17% premarket after offering headlines
EQUITY | Jul 17, 2026, 11:18 AM UTC
H
Market-Moving News for July 17th
NFLX: 10% | Netflix shares are trading lower after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. Also, the company narrowed its FY26 sales guidance with its midpoint be
EARNINGS | Jul 17, 2026, 11:16 AM UTC
L
RGNX Regenxbio announces pricing of public offering of common stock and pre-funded warrants Regenxbio - expects gross proceeds of about $100
RGNX Regenxbio announces pricing of public offering of common stock and pre-funded warrants Regenxbio - expects gross proceeds of about $100M from offering - Prices public offering of 10M shares at $9 and 1.11M pre-funde
EQUITY | Jul 17, 2026, 11:00 AM UTC
H
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Shares of Callan JMB Inc (NASDAQ: CJMB ) rose sharply in pre-market trading following the announcement that Callan JMB signed a strategic partnership with Alabama State University to build an integrated pharmaceutical ma
MACRO | Jul 17, 2026, 08:48 AM UTC
L
RGNX -12% post mkt after offering headlines
RGNX -12% post mkt after offering headlines
EQUITY | Jul 16, 2026, 08:29 PM UTC
L
RGNX Regenxbio announces proposed public offering of common stock
RGNX Regenxbio announces proposed public offering of common stock
EQUITY | Jul 16, 2026, 08:27 PM UTC
M
CAPR Falls 13%
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
EQUITY | Jun 26, 2026, 06:06 PM UTC
M
RGNX Completes Dosing
REGENXBIO completes dosing in its confirmatory study of RGX-202 gene therapy for Duchenne muscular dystrophy
EQUITY | Jun 24, 2026, 11:18 AM UTC
H
RGNX Completes Dosing
REGENXBIO completes dosing in confirmatory study of RGX-202, marking completion of registrational development program and supporting planned BLA submission in Q3 2026
EQUITY | Jun 24, 2026, 11:05 AM UTC
H
RGNX: FDA Reconsiders Gene Therapy
Regenxbio aligns with FDA on next steps for potential accelerated approval of Navsunli gene therapy
EQUITY | Jun 22, 2026, 01:23 PM UTC
H
RGNX Seeks FDA Approval
REGENXBIO plans to resubmit its one-time gene therapy for Hunter Syndrome to the FDA after a path forward was established.
EQUITY | Jun 22, 2026, 11:35 AM UTC
H
RGNX Aligns with FDA
REGENXBIO announces alignment with FDA on path forward for NAVSUNLI BLA resubmission for accelerated approval
EQUITY | Jun 22, 2026, 11:31 AM UTC
H
RGNX: FDA Reverses Rejection
Regenxbio says FDA will reverse rejection of third rare-disease drug
EQUITY | Jun 22, 2026, 10:41 AM UTC